The impact of close surveillance on pregnancy outcome among women with a prior history of antepartum complications attributed to thrombosis: a cohort study

Raed Salim1,2, Tali Czarnowicki1, Zohar Nachum1,2 and Eliezer Shalev*1,2

Address: 1Department of Obstetrics and Gynecology, HaEmek Medical Center, Afula, Israel and 2Rappaport Faculty of Medicine, Technion, Haifa, Israel

Email: Raed Salim - salim_ra@clalit.org.il; Tali Czarnowicki - tali.czar@gmail.com; Zohar Nachum - nachum_zo@clalit.org.il; Eliezer Shalev* - shaleve@tx.technion.ac.il

* Corresponding author

Abstract

Background: There is limited evidence, so far, as to the optimal management of women with a prior obstetric history of antepartum complications attributed to thrombosis. We aimed to investigate the contribution of close antepartum surveillance on pregnancy outcome among women with prior antepartum complications attributed to thrombosis.

Methods: The study was conducted on all women who were delivered, conceived and delivered again between January 2000 and January 2006 at a university teaching hospital. Women included were managed in previous pregnancy at a low risk setting and had unpredicted antepartum complications occurring at a gestational age of 23 weeks or more. Antepartum complications considered were intrauterine fetal death, neonates who were small for gestational age, severe pre-eclampsia and placental abruption. All women were tested for the presence of thrombophilia after delivery. In the following pregnancy, only women found to have any thrombophilia (thrombophilic group) were treated with enoxaparin. Both the thrombophilic group and the non-thrombophilic group (tested negatively for thrombophilia) were managed and observed closely at our high-risk pregnancy clinic.

Results: Ninety-seven women, who conceived at least once after the diagnosis of the relevant antepartum complications, were included in this study. Forty-nine had any thrombophilia and 48 tested negatively. Composite antepartum complications (all antepartum complications considered) were reduced significantly after close antepartum surveillance in both groups. Mean birth weight and mean gestational age improved significantly and were comparable between the groups.

Conclusion: Close antepartum surveillance may contribute to improvement in the perinatal outcomes of women with prior antepartum complications attributed to thrombosis.

Background

Severe pre-eclampsia, intrauterine growth restriction, intrauterine fetal death, and placental abruption affect 8% of pregnant women and collectively contribute to the largest proportion of maternal and fetal mortality and morbidity [1]. Evidence has accumulated to suggest that these...
antepartum complications could have a common thrombogenic basis that manifested in the placenta as placental infarction, perivillous fibrin deposition, intervillous thrombosis and placental floor infarction [2, 3]. Although acquired and inherited thrombophilia had been reported to increase significantly the incidence of antepartum complications attributed to thrombosis [4-8], Mousa et al reported that no different or specific histological pattern could be identified among women with antepartum complications when thrombophilia positive and thrombophilia negative groups were compared [3].

There is limited evidence, so far, as to the optimal management of women with a prior obstetric history of antepartum complications attributed to thrombosis. Since these women are considered at a high risk of an adverse maternal or fetal outcome in subsequent pregnancies [1], we aim in this study to investigate the possible beneficial effect of close antepartum surveillance among these women who conceived and delivered again at our institution.

Methods
Women who had a previous pregnancy with antepartum complications occurring at a gestational age of 23 weeks or more were followed and tested for thrombophilia. Antepartum complications considered were unexplained intrauterine fetal death, neonates who were small for gestational age (SGA), severe pre-eclampsia and placental abruption. SGA was defined as birth weight below the 10th percentile. Severe pre-eclampsia was defined as blood pressure measuring above 140/90 combined with proteinuria (300 mg/24 h) and accompanied with one or more of the following complications: worsening blood pressure to a level above 160/110, HELLP syndrome (hemolysis, low platelet count and elevated liver enzymes), persistent severe headache or visual disturbances, persistent severe epigastric pain, nausea and vomiting, eclampsia, pulmonary edema, oliguria (urine output less than 500 cc/24 h), proteinuria of 5 g or more per 24 h and fetal growth restriction (below the 5th percentile). The study was conducted at a university teaching hospital on all women who were delivered, tested for thrombophilia after delivery, conceived and delivered again between January 2000 and January 2006. Women were asked about bleeding episodes, signs of thrombosis, and symptoms of bone pain. Levels of platelets were followed monthly.

We compared perinatal outcomes within and between the groups before and after close surveillance. Perinatal outcomes included the reappearance of one or more of the thrombophilic complications considered (fetal death, SGA, severe pre-eclampsia and placental abruption), neonatal birth weight and Apgar score. Other parameters collected were maternal age and ethnicity. The local Institutional Review Board approved the study.
Statistical analysis
Data analysis was performed using the SPSS 14 statistical package (SPSS, Chicago, IL). Comparison of binary variables between thrombophilic and non-thrombophilic groups, were analyzed by Chi-square test or Fisher’s exact test as appropriate. T test or Mann Withney test were used to compare continuous variables between the two independent groups. To assess the influence of treatment on the variables in each group, McNemar, Paired T test or Wilcoxon signed ranks test were applied as appropriate. Proportion of live born neonates per woman was calculated as number of live born neonates divided by number of births per woman. The same calculation was made regarding the proportion of preterm deliveries and complicated pregnancies per woman. A p value < 0.05 was considered significant.

Results
Ninety-seven women, who conceived at least once after the diagnosis of the relevant antepartum complications, were included in this study. Of all the 97 women, 49 had any thrombophilia and 48 tested negatively for thrombophilia. Of all the 97 women, 54 were Arabs and 43 were Jews. Of the 54 Arab women, 34 (63%) had thrombophilia compared to 15 out of 43 (35%) Jews (p = 0.008, OR 3.2, 95% CI 1.4 to 7.3). The thrombophilic profile of the thrombophilic group is presented in table 1. Thirty-nine women had a solitary thrombophilic defect, while 10 women had a combined thrombophilia. Factor V Leiden (FVL) was the most common thrombophilic defect, presented in 16 out of 39 women (41%) as a solitary finding and in 8 of 10 women (80%) as part of a combined defect.

Among the thrombophilic group, the number of women with at least one live born neonate was significantly increased, and the composite antepartum complications (all antepartum complications considered) were reduced significantly after close surveillance (table 2). In addition, the incidence of antepartum complications per woman, before and after close surveillance combined with LMWH treatment, was also significantly reduced (table 3). Gestational age at delivery was 33 weeks (+/- 5.9) compared with 37.3 weeks (+/- 3.4), (p < 0.01), and the mean birth weight among women who had live born neonates before and after close surveillance was 2353 g (+/- 756) and 2869 g (+/- 641) respectively (p < 0.01).

Among the non-thrombophilic group, the number of women with at least one live neonate was not increased significantly following close surveillance; however, the incidence of live born neonates per woman, before and after close surveillance, was significantly increased (table 2 and 3). Composite antepartum complications were reduced significantly after close surveillance. The number of women who had severe pre-eclampsia or delivered small for age neonates did not differ significantly (table 2 and 3). Gestational age at delivery was 32.4 weeks (+/- 4.8) compared with 36.4 weeks (+/- 3.9) after close surveillance (p < 0.01). The mean birth weight among women who had live born neonates before and after close surveillance was 2213 g (+/- 918) and 2592 g (+/- 820) respectively (p = 0.03). Before close surveillance, all the parameters studied were comparable between the thrombophilic group and the non-thrombophilic group (table 4). After close surveillance, beside the incidence of preterm deliveries, each individual antepartum complications studied was comparable between the groups (table 4). Gestational age and birth weight did not differ between the groups before and after close surveillance. Among the thrombophilic group, 19.4% of women delivered by cesarean section compared to 24.5% among the non-thrombophilic group after close surveillance (p = 0.5). Of all the vaginal deliveries, 28% and 40% were induced in the thrombophilic group and the non-thrombophilic group respectively (p = 0.3). Three cases of postpartum bleedings were noticed only within the thrombophilic group (p = 0.3). Among all live neonates, none had an Apgar score of less than 7 at 5 minutes in either group.

Table 1: The thrombophilic profile of the 49 women who belonged to the thrombophilic group.

| Single thrombophilia                        | No. | Combined thrombophilia                   | No. |
|---------------------------------------------|-----|------------------------------------------|-----|
| Factor V Homozygote                        | 1   | Factor V Heterozygote + MTHFR homozygote | 4   |
| Factor V Heterozygote                      | 15  | Factor V Heterozygote + Protein S deficiency | 3   |
| Factor II Homozygote                       | 0   | Factor V Homozygote + Protein S deficiency | 1   |
| Factor II Heterozygote                     | 5   | ANT III deficiency + MTHFR homozygote    | 1   |
| MTHFR homozygote                           | 7   | Protein S deficiency + MTHFR homozygote  | 1   |
| Protein C deficiency                       | 0   |                                          | 3   |
| Protein S deficiency                       | 3   |                                          | 3   |
| ANT III deficiency                         | 0   |                                          | 0   |
| Antiphospholipid antibodies                | 8   |                                          |     |

MTHFR = methylenetetrahydrofolate reductase.
ANT = antithrombin.
We did not observe any case of heparin-induced thrombocytopenia among the 49 women treated with LMWH. Likewise, there were no clinical manifestations of bone pain or bleeding complications related to LMWH treatment among the women.

**Discussion**

The present report demonstrates that close antepartum surveillance at specialized clinics may contribute to improvement in the perinatal outcomes of women with prior antepartum complications attributed to thrombosis regardless of the presence of thrombophilia detected by our testing methods. Among these women, the incidence of any thrombophilic defect was 51%, which is, similar to that reported in the literature [10]. The FVL mutation was the most common type of thrombophilia, accounting for 49% of all the thrombophilic defects. The incidence of thrombophilia was significantly higher among Arabs compared to Jews. The high incidence of thrombophilia among Israel’s Arabs compared to Jews maybe explained by the high rate of consanguinity reported in that population [11,12].

|                      | Thrombophilic group (N = 49) | Non-thrombophilic group (N = 48) | P*          |
|----------------------|-----------------------------|---------------------------------|-------------|
|                      | Before close surveillance N (%) | After close surveillance N (%) | Before close surveillance N (%) | After close surveillance N (%) | P*          |
| Live born neonate    | 35 (71)                      | 46 (94)                         | 0.004       | 40 (83)                      | 44 (92) | 0.1         |
| Preterm delivery     | 20 (41)                      | 5 (10)                          | 0.001       | 27 (56)                      | 16 (33) | 0.052       |
| Complicated pregnancies | 49 (100)                   | 6 (12)                          | <0.001      | 48 (100)                     | 19 (40) | <0.001      |
| SGA                  | 21 (43)                      | 5 (10)                          | <0.001      | 21 (44)                      | 12 (25) | 0.06        |
| IUFD                 | 25 (51)                      | 2 (4)                           | <0.001      | 20 (42)                      | 3 (6)   | <0.001      |
| Severe pre-eclampsia | 9 (18)                       | 1 (2)                           | 0.02        | 10 (21)                      | 4 (8)   | 0.1         |
| Placental abruption  | 18 (37)                      | 1 (2)                           | <0.001      | 18 (38)                      | 5 (10) | 0.004       |

* McNemar test
Complicated pregnancies = the reappearance of one or more of the thrombophilic complications considered (fetal death, SGA, severe pre-eclampsia and placental abruption)
SGA = neonate small for gestational age
IUFD = intrauterine fetal death

Table 3: Comparison of the proportion of complications per woman within the thrombophilic and non-thrombophilic groups before and after close surveillance.

|                      | Thrombophilic group (N = 49) | Non-thrombophilic group (N = 48) | P*          |
|----------------------|-----------------------------|---------------------------------|-------------|
|                      | Before close surveillance | After close surveillance | Before close surveillance | After close surveillance | P*          |
| Live born neonate    | 63 (43) [80]                | 96 (20) [100]                  | <0.001      | 74 (38) [100]               | 96 (21) [100] | 0.002      |
| Preterm deliveries    | 30 (42) [0]                 | 9 (29) [0]                     | 0.01        | 42 (44) [33]                | 32 (46) [0] | 0.4         |
| Complicated pregnancies | 70 (32) [67]               | 11 (31) [0]                    | <0.001      | 63 (35) [50]                | 35 (46) [0] | 0.004      |

The data are presented as mean proportion, (standard deviation) and [median]
* Wilcoxon Signed Rank Test
In this study, 49% of the women who had antepartum complications were tested negatively for thrombophilia and therefore were not treated with LMWH. After close surveillance alone in subsequent gestations, a significant improvement was observed in composite fetal outcome compared to previous gestations. Nevertheless, and probably expected, the number of women who had severe pre-eclampsia or delivered SGA neonates did not differ significantly with close surveillance alone. Close surveillance alone decreased significantly the incidence of IUFDs per woman. Moreover, gestational age and birth weight were both improved, probably due to the opportunity of prolonging the gestational age under close surveillance.

When comparing perinatal outcome between the groups, antepartum complications were reduced significantly in both groups after close surveillance. Moreover, gestational age at delivery, birth weight and the incidence of live born neonate per woman were comparable between the groups.

Comparing the thrombophilic and the non-thrombophilic group, who tested negatively for the thrombophilic defects studied, might seem ill advised. Nevertheless, both groups share probably the same utero-placental histopathology. Mousa et al reported that no specific histological pattern could be identified among women with antepartum complications when thrombophilia positive and thrombophilia negative groups were compared and concluded that a poor correlation exists between thrombophilia status and pathological changes of the placenta in women with antepartum complications [3]. Moreover, it cannot be ruled out that the non-thrombophilic group possesses thrombophilic defects that are unknown or were not studied in this report [22]. We did not stratify the obtained results with the level of fasting total homocysteine, because all women were taking folic acid from at least 1 month before conception [23].

Moreover, we did not examine the maternal plasma levels of coagulation factor VIII, which had been reported to be associated with an increased risk for recurrent early pregnancy loss [24], or for protein Z deficiency and positive antiprotein Z antibodies, which had been described to increase the severity of the prothrombotic phenotype of FVL [25]. Whether the non-thrombophilic group has an unrecognized thrombophilia or not, close surveillance without any other treatment improved their perinatal outcomes.

**Conclusion**

Although, and due to ethical issues, the women in both groups were not randomized and all got the same close antepartum surveillance, this study reveals that close surveillance at a specialized clinic may improve the perinatal outcomes of both thrombophilic and non-thrombophilic women with prior antepartum complications attributed to thrombosis. However, this study does not separate the effect of LMWH and close antepartum surveillance on pregnancy outcome among the thrombophilic group and it still needs to be determined whether the additional treatment of LMWH is better than close surveillance alone. While this study cannot answer the latter issue, its results may be considered an intermediate step in allowing placebo to be compared to LMWH during pregnancy in thrombophilic women with previous placental dysfunction.

**Competing interests**
The authors declare that they have no competing interests.

---

### Table 4: Comparison between perinatal outcomes of thrombophilic and non-thrombophilic groups before and after close surveillance

|                                      | Before close surveillance | After close surveillance |
|--------------------------------------|---------------------------|--------------------------|
|                                      | Thrombophilic group (N = 49) | Non-thrombophilic group (N = 48) | P | Thrombophilic group (N = 49) | Non-thrombophilic group (N = 48) | P |
| Live born neonate*                   | 63 (43) [80]              | 74 (38) [100]            | 0.2† | 96 (20) [100]              | 96 (21) [100]              | 0.9‡ |
| Preterm deliveries*                  | 30 (42) [0]               | 42 (44) [33]             | 0.1† | 9 (29) [0]                 | 32 (46) [0]                 | 0.005† |
| Number of women who delivered at least one SGA (%) | 21 (43)                  | 21 (44)                  | 0.9‡ | 5 (10)                     | 12 (25)                     | 0.06‡ |
| Number of women who delivered at least one IUFD (%) | 25 (51)                  | 20 (42)                  | 0.4‡ | 2 (4)                      | 3 (6)                       | 0.7§ |
| Severe pre-eclampsia (%)             | 9 (18)                    | 10 (21)                  | 0.8‡ | 1 (2)                      | 4 (8)                       | 0.2§ |
| Placental abruption (%)              | 18 (37)                   | 18 (38)                  | 0.9‡ | 1 (2)                      | 5 (10)                      | 0.1§ |

* The data are presented as mean proportion, (standard deviation) and [median]
† Mann Whikey test
‡ Chi-square test
§ Fisher’s exact test
SGA = neonate small for gestational age
IUFD = intrauterine fetal death.

---
Authors’ contributions
RS and ES designed the research, supervised the data collection, assisted in the statistical analysis, and wrote the manuscript. TC and ZN collected and maintained the data and assisted in writing the manuscript. All authors read and approved the final manuscript.

Acknowledgements
We thank Idit Lavi, Department of Community Health and Epidemiology (IL), Carmel Medical Center, Haifa, Israel, regarding the statistical support and we appreciate her advice and contribution for the study. Idit Lavi received no compensation.

References
1. Hossain N, Paidas MJ: Adverse pregnancy outcome, the utero-placental interface, and preventive strategies. Semin Perinatol 2007, 31:208-212.
2. Younis JS, Samueloff A: Gestational vascular complications. Best Pract Res Clin Haematol 2003, 16:135-151.
3. Mousa HA, Alfirievic Z: Do placental lesions reflect thrombophilia state in women with adverse pregnancy outcome? Hum Reprod 2000, 15:1830-1833.
4. Weiner Z, Beck-Bruchter R, Weiss A, Hujirat Y, Shalev E, Shalev SA: Thrombophilia and stillbirth: possible connection by intrauterine growth restriction. BJOG 2004, 111:780-783.
5. Preston FE, Rosendaal FR, Walker ID: Increased fetal loss in women with heritable thrombophilia. Lancet 1996, 348:913-916.
6. Many A, Kupferminc MJ: Thrombophilia and adverse pregnancy outcome. Hematologica 2003, 88:729-731.
7. Kupferminc MJ, Eldor A: Inherited thrombophilia and gestational vascular complications. Semin Thromb Hemost 2003, 29:185-194.
8. Wiener-Megnagi Z, Ben-Shlomo I, Goldberg Y, Shalev E: Resistance to activated protein C and the Leiden mutation: high prevalence in patients with abruptio placentae. Am J Obstet Gynecol 1998, 179:1565-1567.
9. Preston FE, Rosendaal FR, Walker ID, Briet E, Berntorpe E, Conard J, Fontcuberta J, Makris M, Mariani G, Noteboom W, Fabinger I, Legnani C, Scharrer I, Schulman S, Meier F van der: Increased fetal loss in women with heritable thrombophilia. Lancet 1996, 348:913-916.
10. Brenner B, Kupferminc MJ: Inherited thrombophilia and poor pregnancy outcome. Best Pract Res Clin Obstet Gynaecol 2003, 17:427-439.
11. Zlotogora J, Leventhal A, Amitai Y: The impact of congenital malformations and Mendelian diseases on infant mortality in Israel. IMAM 2003, 5:416-418.
12. Vardi-Saliterim R, Friedlander Y, Cohen T: Consanguinity in a population sample of Israeli Muslim Arabs, Christian Arabs and Druze. Ann Hum Biol 2002, 29:422-431.
13. Riyazi N, Leeda M, de Vries JI, Huisjes PC, van Geijn HP, Dekker GA: Low-molecular-weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: a preliminary study. Eur J Obstet Gynecol Reprod Biol 1998, 80:49-54.
14. Hunt BJ, Doughty HA, Majumdar G, Copplestone A, Kerslake S, Buchanan N, Hughes G, Khamashta M: Thromboprophylaxis with low molecular weight heparin (Fragmin) in high-risk pregnancies. Thromb Haemost 1997, 77:39-41.
15. Gris JC, Mercier E, Quere I, Lavigne-Lissalde G, Cochery-Nouvellon E, Hofert M, Ripart-Neveu S, Tailland ML, Dauzat M, Marès P: Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 2004, 103:3695-3699.
16. Rai R, Cohen H, Dave M, Regan L: Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997, 314:253-257.
17. Kutteh WH: Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996, 174:1584-1589.
18. Farquharson RG, Quenby S, Greaves M: Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 2002, 100:408-413.
19. Kalk JJ, Huisjes AJ, de Groot CJ, van Beek E, van Pampus MG, Spanderman ME, van Eyck J, Oei SG, Bezemer PD, de Vries JI: Recurrence rate of pre-eclampsia in women with thrombophilia influenced by low-molecular-weight heparin treatment? Neh J Med 2004, 62:83-87.
20. Pabinger I, Vormittag R: Thrombophilia and pregnancy outcome. J Thromb Haemost 2005, 3:1603-1610.
21. Blumenfeld Z, Brenner B: Thrombophilia-associated pregnancy wastage. Fertil Steril 1999, 72:765-774.
22. Coulam CB, Wallis D, Weinstein J, Dasgupta DS, Jeyendran RS: Comparison of thrombophilic gene mutations among patients experiencing recurrent miscarriage and deep vein thrombosis. Am J Reprod Immunol 2008, 60:426-431.
23. Nelen WL: Hyperhomocysteinaemia and human reproduction. Clin Chem Lab Med 2001, 39:758-763.
24. Dossenbach-Glaninger A, van Trotsenburg M, Krugluger W, Dossenbach MR, Oberkanins C, Huber J, Hopmeier P: Elevated coagulation factor VIII and the risk for recurrent early pregnancy loss. Thromb Haemost 2004, 91:694-699.
25. Kemkes-Matthes B, Nees M, Kuhnert G, Matzendorf A, Matthes KJ: Protein Z influences the prothrombotic phenotype in factor V Leiden patients. Thromb Res 2002, 106:183-185.